Klaricid

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Klaricid

Property Description
Active ingredient Clarithromycin
Form Oral Tablets, Oral Suspension, IV Solution
Pharmacological class Macrolide Antibiotic
General purpose Fights systemic bacterial infections
Origin Semisynthetic Compound

Klaricid: Defining the Macrolide Antibiotic

Klaricid is the brand name for a medicinal preparation containing the active ingredient Clarithromycin, a substance classified as a semisynthetic macrolide antibiotic. The drug demonstrates efficacy against a broad spectrum of pathogens. This core compound is chemically derived from erythromycin, an older macrolide agent, and is utilized for systemic use against a range of susceptible bacterial pathogens. Unlike some older antibiotics, Clarithromycin offers the advantage of enhanced stability in the acidic environment of the stomach. Klaricid is available strictly as a prescription-only medicine, underscoring its therapeutic potency.


General Therapeutic Purpose and Action Profile

The overall purpose of Klaricid is to fight systemic bacterial infections by effectively controlling the growth and spread of harmful bacteria throughout the body. The medicine acts as a bacteriostatic agent, which inhibits the ability of bacteria to multiply. This is achieved by stopping bacteria from producing the proteins they need to grow and spread, a mechanism utilized for its effectiveness against sensitive pathogens. This action is achieved through a targeted molecular mechanism: Clarithromycin penetrates the bacterial cell and prevents the synthesis of essential proteins. By halting protein production, the drug prevents the bacterial population from escalating, offering the body's immune system the necessary advantage to clear the underlying infection.


Available Forms: Oral Tablets, Suspension, and IV Preparation

Clarithromycin is manufactured for patient use in several principal dosage forms tailored to different patient groups and clinical requirements. These forms include various oral tablets, such as the standard film-coated presentation and the extended-release (XL) formats designed to facilitate patient compliance by reducing dosing frequency. This Klaricid formulation is often differentiated in the market by its granules for oral suspension, a key formulation used for accurate dosing in paediatric patients. Additionally, a formulation is provided for intravenous (IV) solution administration, which is typically reserved for critical care or when the oral route is not feasible.

Regulatory References

  1. NIH: National Library of Medicine

What side effects are possible with Klaricid?

Possible Side Effects and Safety Information for Klaricid (Clarithromycin)

The official regulatory safety profile for Klaricid, a macrolide antibiotic, is defined by classifications of adverse reactions based on incidence, potential systemic effects, and specific population constraints.

Frequency and Common Reactions

Adverse reactions are formally categorized based on frequency observed in clinical data. Common effects, reported in 1% to 10% of patients, primarily involve the Gastrointestinal System, including diarrhea, nausea, vomiting, abdominal pain, and dysgeusia (taste perversion). Effects such as leukopenia and hypersensitivity are classified as Uncommon.

Serious Adverse Reactions

Official labeling documents highlight the potential for serious adverse reactions, which are rare but clinically critical. These include severe skin reactions (SCARs) such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Fatal outcomes have been reported with hepatic failure and potentially life-threatening cardiac arrhythmias, including Torsades de pointes and ventricular fibrillation. Clostridium difficile-associated diarrhea (CDAD) is also a documented serious concern.

Population and Contextual Safety Notes

Specific safety constraints are noted for certain patient groups. The medicine is formally contraindicated in cases of severe hepatic failure combined with renal impairment and for individuals with pre-existing conditions like congenital QT prolongation or uncorrected hypokalemia/hypomagnesemia. The potential for long-term cardiovascular risk has been documented in patients with existing heart disease, occurring one year or more after treatment completion. Certain effects, such as deafness and psychiatric disorders, have been noted to be reversible upon discontinuation of the drug.

Overdose and Emergency Response

The regulatory documentation for Klaricid (Clarithromycin) overdose defines a profile focused on serious systemic risks and mandated emergency action.

Property Official Regulatory Statement
Documented Manifestations Overdose is commonly associated with pronounced gastrointestinal symptoms, including severe stomach pain, nausea, vomiting, and diarrhea. Postmarketing reports have also cited manifestations of altered mental status, such as confusional state and hallucination.
Serious Physiological Outcomes The primary life-threatening risk involves the cardiovascular system, where overdose carries the potential to induce QT interval prolongation and subsequent ventricular arrhythmias, including Torsades de Pointes. Renal failure is also noted in postmarketing surveillance.
Emergency Action Required Individuals experiencing any documented symptom of overdose must seek emergency medical attention immediately. In the US, the official instruction is to call the Poison Help line or emergency services. Immediate medical help is required when any overdose symptom or cardiac change occurs.
Population Note The prescribing information notes that geriatric patients may exhibit an increased susceptibility to the drug’s effects on the QT interval, highlighting a specific risk factor in overdose.

Overdose Management Profile

Management is strictly defined as symptomatic and supportive treatment, as regulatory texts confirm that no specific antidote is known for clarithromycin overdose. Because of the serious cardiotoxicity risks, ECG monitoring is an essential procedural requirement. Furthermore, regulatory documentation notes that measures such as hemodialysis or peritoneal dialysis are not expected to significantly affect plasma concentrations.

Therapeutic Uses of Klaricid

Klaricid (Clarithromycin) is commonly used to manage a range of bacterial infections across several key organ systems. This medication is applied in contexts where a bacterial pathogen is causing symptomatic discomfort and temporary functional strain. Its core benefit is to provide support that helps ease the overall symptom burden by supporting the process of addressing the systemic bacterial cause.


What Klaricid Helps Manage: Symptom & Condition Overview

The medication is relevant for easing symptoms that interfere with daily comfort across several therapeutic domains. It is commonly used across conditions presenting with acute episodes in the respiratory system (including pneumonia, bronchitis, and sinusitis), uncomplicated skin and soft tissue infections (like cellulitis), and acute otitis media (ear infection). Furthermore, it plays a role in managing the Helicobacter pylori (H. pylori) bacterium linked to duodenal ulcers and is relevant for the management and prevention of Mycobacterium Avium Complex (MAC) in high-risk patients.

“It helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during symptomatic periods.”


Quick Fact: Support for Acute Discomfort

Quick Fact: Support for Acute Discomfort. Klaricid is commonly used when symptoms intensify and supportive relief is needed to address systemic discomfort, including fever and localized pain, which are associated with acute bacterial infections.

Regulatory References

  1. DailyMed (NIH) Official Drug Label

Eligibility and Restrictions for Use

Klaricid (clarithromycin) is an antibiotic that is contraindicated (must not be used) for several groups of patients due to the risk of serious side effects or dangerous drug interactions.

Contraindicated Populations

  • Patients with a known allergy to clarithromycin, erythromycin, or any macrolide antibiotic.
  • Individuals with a history of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use.
  • Patients with pre-existing heart rhythm problems, such as prolonged QT interval or ventricular cardiac arrhythmia (including Torsades de Pointes).
  • Those with severe liver failure combined with kidney impairment.

Strictly Prohibited Drug Combinations

Klaricid must not be taken with certain medications, including:

  • Specific drugs for migraines (ergot alkaloids, e.g., ergotamine or dihydroergotamine).
  • Certain cholesterol-lowering medicines (statins, e.g., lovastatin or simvastatin).
  • Specific medications that can prolong the QT interval (e.g., astemizole, cisapride, pimozide, terfenadine).
  • Colchicine, particularly in those with kidney or liver impairment.

Special Considerations

  • Pregnancy and Lactation: Use is generally not recommended in pregnant women unless no appropriate alternative treatment is available. The drug passes into breast milk, requiring careful consideration or temporary cessation of nursing.
  • Pediatric Use: The immediate-release tablet form is typically not recommended for children younger than 12 years.

What should I know about interactions with other medicines?

Klaricid (clarithromycin) is a potent inhibitor of the cytochrome P450 enzyme CYP3A4, which is responsible for the metabolism of many other medications. Co-administration can significantly increase the concentration of these drugs in the bloodstream, leading to an increased risk of serious side effects or toxicity. Therefore, it is critical to inform your doctor or pharmacist of all medications, including over-the-counter drugs, vitamins, and herbal supplements, before starting Klaricid.

Contraindicated and Major Interactions

Some medicines are absolutely contraindicated (should not be taken) with Klaricid due to the risk of severe or life-threatening adverse reactions:

Drug Class Examples of Interacting Medicines
Statins (Cholesterol Lowering) Simvastatin, Lovastatin (Risk of severe muscle problems, including rhabdomyolysis)
Ergot Alkaloids (Migraine) Ergotamine, Dihydroergotamine (Risk of acute vascular constriction and reduced blood flow)
Antipsychotics Pimozide (Risk of serious, abnormal heart rhythms)
Other Colchicine (Gout treatment), Cisapride (Discontinued in many regions)

Other Significant Interactions

Klaricid may also require dosage adjustments or close monitoring when taken with the following:

  • Other Statins: Atorvastatin (dose must be significantly reduced or temporarily stopped).
  • Anticoagulants (Blood Thinners): Warfarin (increased risk of bleeding; necessitates frequent blood monitoring).
  • Antiepileptic Drugs: Carbamazepine, Phenytoin (increased drug levels and potential toxicity).
  • Benzodiazepines (Sedatives): Midazolam, Triazolam (increased sedative effects and drowsiness).
  • Heart Medicines: Digoxin, certain Calcium Channel Blockers (e.g., Verapamil), and drugs that prolong the QT interval (e.g., Amiodarone, Quinidine). The combination can increase levels and risk of toxicity or dangerous heart rhythms.

Mechanism of Action

Molecular Targeting of the Bacterial Ribosome

The primary mechanism involves Clarithromycin binding reversibly to the 50S ribosomal subunit within bacterial cells, specifically obstructing the nascent peptide exit tunnel (NPET) . This targeted molecular interference inhibits the essential process of bacterial protein synthesis (translation), resulting in the cessation or arrest of bacterial growth. The immediate physiological result is a bacteriostatic effect, meaning the bacteria are prevented from replicating. The reduced proliferation shifts the balance, enabling the host's immune system to process and eliminate the stabilized bacterial population.


Enhanced Delivery and Dual-Component Activity

The overall action utilizes two components: the drug is metabolized into an active compound, 14-hydroxyclarithromycin, which acts synergistically with the parent drug, contributing to a combined inhibitory profile. Furthermore, Clarithromycin demonstrates an affinity for concentrating within host phagocytic immune cells. This mechanism enables localized delivery of the active drug to tissue compartments containing phagocytic cells. These mechanisms combine to achieve targeted inhibition of bacterial proliferation.

Dosage and Administration Information

How to Use Klaricid: Official Administration Guidelines

Clarithromycin (Klaricid) administration follows established protocols which detail the approved route, frequency, and preparation of each formulation. The medicine is primarily administered via the oral route (tablets or suspension), with the intravenous (IV) infusion route reserved for cases requiring parenteral therapy.


Official Dosing and Frequency Patterns

Formulation Type Standard Adult Frequency Special Instruction
Immediate-Release (IR) Tablets/Suspension Twice Daily (Every 12 hours) May be taken with or without food.
Extended-Release (XL) Tablets Once Daily (Every 24 hours) Must be taken with food; swallow whole, do not crush or chew.

Procedural and Population Rules

Administration duration typically spans 7 to 14 days for most acute regimens. The dosage is typically reduced by one-half for adults with severe renal impairment (creatinine clearance less than 30 mL/min), an adjustment detailed in the prescribing information.

For pediatric patients (aged 6 months to 12 years), the oral suspension is the appropriate form, with dosing calculated based on body weight, typically 7.5 mg/kg every 12 hours. The tablets are not recommended for children under 12 years. The IV formulation requires dilution and must be administered as a slow infusion over 60 minutes when used in a supervised setting.

These instructions define the procedural framework for using the medicine, establishing the necessary conditions and administration timing for each approved formulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Klaricid


Evidence for Use in Acute Respiratory System Infections

Research related to acute infections of the upper and lower respiratory tract, such as pneumonia, bronchitis, and sinusitis, includes Randomized Controlled Trials (RCTs) and comparative studies. These studies were applied in studies examining patient-reported experiences in both adults and paediatric patients with conditions associated with acute or disruptive episodes. Researchers focused on outcomes related to physical discomfort and systemic or functional imbalance, specifically looking at measurements of Clinical Outcome Rate and the Bacteriological Clearance Rate (measuring changes in the specific pathogen).

The studies monitored measured outcomes over defined time intervals, documenting patterns observed in the studied populations at the end of treatment and during a follow-up assessment (Test-of-Cure). Studies observed patterns where measured outcomes related to physical discomfort were documented alongside outcomes for other antibiotic comparators. This research contributes to the broader evidence landscape for understanding conditions characterized by heightened symptoms.

What remains uncertain is the need for continuous research and monitoring to assess how evolving macrolide resistance patterns in common respiratory pathogens may influence the measured outcomes today. The evidence highlights patterns where separating the observed outcomes from factors beyond the primary antimicrobial effect remains difficult.

Evidence for Use in Helicobacter pylori Eradication

Research examined Klaricid for its inclusion in multi-drug regimens applied to the H. pylori bacterium, which is associated with duodenal and gastric ulcers. The research explored short-term symptom changes in adults within multi-drug research scenarios where Klaricid was a component. Studies focused on outcomes reflecting daily functioning, with a primary focus on the Study Endpoint: Pathogen Clearance Rate, which evaluated outcomes related to this rate several weeks after the study conclusion.

Findings describe patterns observed in the studies related to the measured pathogen reduction and associated outcomes capturing phases of heightened symptom activity. However, data show patterns related to variable success rates that was observed in some studies, indicating that local antibiotic resistance levels were associated with the measured outcome. The evidence contributes to understanding symptom patterns and contextualizing how patients reported their experience during these conditions involving periods of heightened symptoms.

Certainty remains low regarding the measured outcomes in regions where high clarithromycin resistance is documented; therefore, results apply only to the populations studied. There is also limited information regarding the generalizability of findings to patients with significant comorbidities who were often excluded from the initial trials.

Evidence for Use in Managing Mycobacterium Avium Complex (MAC)

Research has examined Klaricid as a component within multi-drug regimens applied in research contexts involving Mycobacterium Avium Complex (MAC) disease. Studies monitored patients with conditions marked by functional limitations over defined time intervals, often for extended observation periods of six months to a year or more. Research was conducted during periods of increased symptom activity in high-risk groups, including adults and children with advanced HIV infection.

Studies reported measured microbiological outcomes. Research describes Klaricid as a component in multi-drug regimens cited by guidelines for this condition. Findings help contextualize how patients reported their experience. Studies reported patterns where measured outcomes related to pathogen reduction was observed following the long-term, multi-drug research scenario.

Comparative evidence is lacking, as there are limited Randomized Controlled Trials that directly compare Klaricid's long-term outcomes against other macrolides (such as azithromycin) specifically for chronic pulmonary MAC. The complex nature of the multi-drug regimens required for this condition makes it difficult to isolate the specific contribution of Klaricid to the overall microbiological outcome.


Follow-up Durations and Long-Term Data

The research surrounding Klaricid primarily utilized short-term follow-up durations for acute infections, typically assessing outcomes within weeks after the conclusion of the study. For severe or chronic conditions, such as MAC, follow-up durations were more extensive, reflecting the long observation period required. Evidence contributes to understanding symptom patterns across these intervals.

However, data are still emerging regarding the durability of response and long-term effects are not fully established after the initial follow-up period has concluded. There is limited information for long-term outcomes related to preventing recurrence or assessing sustained symptom patterns for most indications.

Evidence in Special Populations

Research has explored the use of Klaricid in specific age demographics. Klaricid was evaluated in trials for paediatric patients for conditions like otitis media (ear infection) and pharyngitis, often using formulations evaluated in the study. Studies monitored how symptoms evolved in these younger observed populations.

Similarly, studies have been conducted in older adults, where research examined outcomes related to episodic or acute changes in this age group. However, the results apply only to the populations studied, and data for certain groups remain insufficient, such as those with certain comorbid conditions or specific levels of disease severity. Subgroup findings are uncertain in areas where sample sizes were modest.

What is Still Uncertain About Klaricid Evidence

A primary area of uncertainty across most research streams involves the ongoing and variable issue of antibiotic resistance. Resistance development in key pathogens may influence the measured outcomes in current clinical settings.

Additionally, data for certain groups remain insufficient, such as those with significant, complex comorbidities, as results apply only to the populations studied in the primary trials. While evidence provides insight into short-term changes, long-term effects are not fully established regarding the sustained absence of infection or long-term recurrence rates following the end of the study. Research is ongoing to better characterize these limitations.

Key Studies & References

  1. Clarithromycin - StatPearls [Internet]
  2. Clarithromycin Oral: MedlinePlus Drug Information
  3. Clarithromycin Tablet/Suspension Official Drug Label (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Klaricid (FAQ)


Q: Is Klaricid commonly used for ear infections?

Official information, such as that provided by health authorities, indicates that clarithromycin is used in the treatment of various bacterial infections, which includes ear infections. The selection of this medicine depends on whether it is deemed an appropriate option for the specific bacterial pathogen involved.


Q: Can Klaricid be used for skin infections?

According to official prescribing information, clarithromycin is described for use in treating certain bacterial skin infections. This may include conditions such as cellulitis.


Q: Is there information about Klaricid interacting with grapefruit or grapefruit juice?

Official information indicates that clarithromycin is processed in the body by a specific liver enzyme (CYP3A4). Studies suggest that grapefruit juice can affect the activity of this enzyme, which may potentially alter how the medicine is absorbed or metabolized.


Q: Do official sources describe any known interactions between Klaricid and alcohol?

Official product information and regulatory documents do not typically describe a specific, major drug interaction between clarithromycin and alcohol.


Q: Are there warnings about Klaricid interacting with birth control pills?

Official guidance for hormonal contraceptives often suggests caution when taken with antibiotics, including macrolides like clarithromycin. This is due to the potential for the antibiotic to affect the liver enzymes responsible for metabolizing the contraceptive medicine, which may alter its effectiveness.


Q: Can Klaricid be taken while using common blood-thinning medicines?

Co-administration with certain blood-thinning medicines, such as Warfarin, is the subject of official warnings. Due to the increased risk of serious bleeding (hemorrhage), the prescribing information details that frequent monitoring is necessitated when this combination is used.


Q: Is Klaricid generally compatible with high blood pressure medications?

The official labeling warns that clarithromycin can increase the concentrations of certain heart and blood pressure medicines, specifically Calcium Channel Blockers. This can lead to serious effects, such as a drop in blood pressure (hypotension) or acute kidney injury.


Q: What types of mental health medications are commonly noted for interactions with Klaricid?

Official drug information specifically lists interactions with certain antipsychotic medicines (like Pimozide) and some sedative/anti-anxiety medicines (like Midazolam and Triazolam). These combinations carry a warning because they may increase the risk of serious side effects or over-sedation.


Q: Does Klaricid interact with levothyroxine (thyroid medication)?

Although the medicine interacts with many drugs, official regulatory documents do not typically list a common or major interaction between clarithromycin and levothyroxine (a thyroid medication).


Q: What common over-the-counter pain relievers are officially listed as potential Klaricid interactions?

The most common over-the-counter pain relievers, such as acetaminophen or ibuprofen, are not generally listed in the major drug interaction warnings found in the official regulatory labeling for clarithromycin.


Q: What does official data say about Klaricid and kidney function?

Official guidelines specify that a mandatory dosage reduction is required for adults who have severe renal impairment (poor kidney function). The official safety data also notes that the risk of acute kidney injury can increase when clarithromycin is used alongside certain interacting medications.


Q: Can Klaricid treatment be stopped early if symptoms improve?

Official prescribing information defines a typical duration of therapy, such as 7 to 14 days, which is consistent with the drug’s described action as a bacteriostatic agent. A full course of therapy is outlined in the prescribing information to provide a specified duration for the drug’s intended effect of controlling bacterial growth.


Q: Does regulatory information indicate Klaricid can cause dizziness or confusion?

Official regulatory documents list headache and dizziness as common adverse effects reported by patients. Additionally, confusion is noted in post-marketing reports, particularly when clarithromycin is taken alongside other interacting medicines.


Q: Does Klaricid interact with common herbal supplements like St. John's Wort?

Official drug information includes warnings about interactions with specific herbal supplements, such as St. John's Wort. This supplement has been associated with effects on the liver enzyme (CYP3A4) that processes clarithromycin.


Q: Are there official warnings about Klaricid use in the elderly population?

Official warnings note that the risk of certain serious adverse reactions is observed more frequently in the elderly population, specifically in patients 65 years of age or older. For example, the risk of acute kidney injury may be higher when clarithromycin is co-administered with certain calcium channel blockers.


Q: Can Klaricid affect blood sugar levels, according to regulatory information?

Official prescribing information contains specific warnings regarding the risk of severe hypoglycemia (very low blood sugar). This risk is noted when clarithromycin is taken in combination with certain diabetes medicines, such as sulfonylureas or insulin.


Q: Are there any specific organs the regulatory documents mention monitoring with Klaricid use?

Official safety information highlights specific constraints regarding the liver and the kidneys. Due to the potential for hepatic failure (severe liver problems) and renal impairment (kidney function problems), official documents specify that careful consideration and sometimes dose adjustments are required.


Q: Can individuals with a history of liver problems use Klaricid, according to regulatory guidelines?

Official contraindications classify clarithromycin as a medicine that must not be used in people with a history of liver-related problems that were associated with taking clarithromycin in the past. It is also classified as contraindicated for individuals who have pre-existing severe liver failure combined with kidney impairment.


Q: Are people with known heart conditions generally advised against Klaricid use?

Official warnings advise that physicians should use caution or consider alternative antibiotics for patients who have pre-existing heart disease. The medicine is contraindicated (a formal classification) in patients with specific heart rhythm problems, such as a prolonged QT interval. This is due to a potential increased long-term risk of heart problems that has been noted following treatment.


Q: Does Klaricid show evidence of being effective against H. pylori?

The official indications confirm that clarithromycin is included as part of a combination regimen with other medicines for the management of infections caused by the H. pylori bacterium. This regimen is formally intended to address the bacterium associated with ulcers.


Q: How quickly does Klaricid typically start working, based on general patient expectations?

Information intended for patients, as noted by health authorities, often suggests that for most acute infections, patterns indicate a person may start to feel better within a few days of starting the medicine.


Q: What is the usual duration of a course of Klaricid mentioned in regulatory prescribing information?

Official prescribing information indicates that the typical duration of treatment for most acute regimens spans 7 to 14 days. The precise length of treatment is determined by the specific infection being treated.


Q: Is Klaricid officially known to cause headaches?

Yes, official adverse reaction reports list headache as a common side effect of clarithromycin. A common effect means that it is reported in 1% to 10% of patients who use the medicine.


Q: Can Klaricid be prescribed for walking pneumonia?

Official drug indications include the treatment of certain pneumonia infections. The term 'walking pneumonia' is a common, non-clinical phrase used to describe a milder form of this condition. The formal indication covers the treatment of susceptible bacterial pathogens that cause pneumonia.


Q: Is Klaricid described as an anti-inflammatory drug?

Official drug classification identifies clarithromycin as a macrolide antimicrobial drug or antibiotic, which works to control the growth of susceptible bacteria. It is not formally classified in regulatory documents as an anti-inflammatory drug.


Q: Does taking Klaricid require any changes to diet?

According to official administration guidelines, the Extended-Release (XL) tablet formulation has a mandated condition that it must be taken with food. The immediate-release tablets and oral suspension forms, however, may be taken without regard to food.


Q: What are the official guidelines regarding Klaricid use while breastfeeding?

Official guidance notes that clarithromycin passes into breast milk in very small amounts. However, due to reports of side effects in breastfed babies, such as mild upset stomach or drowsiness, official documents indicate that careful professional consideration is required for its use during this period.


Q: Is there a maximum number of days Klaricid is typically prescribed for?

Official prescribing information defines the typical duration of treatment for most acute bacterial regimens as spanning 7 to 14 days. This defined range represents the standard length for therapy.


Q: Is Klaricid available without a prescription in some countries?

Regulatory documents from major health authorities uniformly define clarithromycin as a prescription-only medicine in their respective jurisdictions. This means it is generally not available for purchase without a valid prescription.

How should Klaricid be stored and disposed of?

Storage and Disposal of Klaricid (Clarithromycin)

Klaricid must be stored according to regulatory requirements to maintain its stability.


Storage Requirements

Formulation Mandatory Conditions
Tablets Store at controlled room temperature (20 C to 25 C), protected from light and excess moisture. Keep in the original, tightly closed container.
Mixed Oral Suspension Must not be refrigerated or frozen. Store at room temperature and use within 14 days of preparation.

All forms of the medication must be kept out of the sight and reach of children to prevent accidental ingestion.


Disposal

Any unused, expired, or leftover Klaricid must be disposed of safely. Discard all unused product and waste material in accordance with local requirements and official guidelines for medication disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Klaricid found in:

A-Z Index: